Core–shell mesoporous silica nanoparticles improve HeLa cell growth and proliferation inhibition by (−)-epigallocatechin-3-gallate by prolonging the half-life
Authors:
- 7 August 2012
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry
- Vol. 22 (37) , 19926-19931
Abstract
(−)-Epigallocatechin-3-gallate (EGCG) is an effective anticancer drug for a variety of cancer cell lines, but it is unstable with a half-life of 30 minutes to 2 hours under different culture conditions for cell apoptosis; EGCG dimers, hydrogen peroxide (H2O2) and other oxidative products are formed. Herein, we report that a multiple core–shell functionalized colloidal mesoporous silica nanoparticle system (CMS) resulted in the electrostatic attraction of EGCG to the surface and pores, alleviating the interaction of free radicals which produced dimers or other polymers. Based on the results of MTT assay, cell cycle analysis and western blot, the loading of EGCG into the CMS increased the anticancer ability of EGCG compared to that of free EGCG being used to treat HeLa cells in the absence of CMS. In addition, fluorescein isothiocyanate (FITC) was entrapped in the core of CMS, which allowed the CMS to simultaneously denote the position of EGCG in cells. These results demonstrate that it is possible to use the CMS platform as a promoter to improve the anticancer ability of the unstable chemotherapeutic agent.Keywords
This publication has 34 references indexed in Scilit:
- Fyn is a novel target of (−)‐epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformationMolecular Carcinogenesis, 2007
- Tea drinking and the risk of biliary tract cancers and biliary stones: A population‐based case–control study in Shanghai, ChinaInternational Journal of Cancer, 2006
- Bioavailability and antioxidant activity of tea flavanols after consumption of green tea, black tea, or a green tea extract supplementThe American Journal of Clinical Nutrition, 2004
- Regular consumption of green tea and the risk of breast cancer recurrence: follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), JapanCancer Letters, 2001
- Cell Cycle Dysregulation by Green Tea Polyphenol Epigallocatechin-3-GallateBiochemical and Biophysical Research Communications, 2000
- Preventive effects of drinking green tea on cancer and cardiovascular disease: Epidemiological evidence for multiple targeting preventionBioFactors, 2000
- Suppression of inducible cyclooxygenase and inducible nitric oxide synthase by apigenin and related flavonoids in mouse macrophagesCarcinogenesis, 1999
- Green tea epigallocatechin gallate shows a pronounced growth inhibitory effect on cancerous cells but not on their normal counterpartsCancer Letters, 1998
- Green tea consumption and the risk of pancreatic and colorectal cancersInternational Journal of Cancer, 1997
- Reduced Risk of Esophageal Cancer Associated With Green Tea ConsumptionJNCI: Journal of the National Cancer Institute, 1994